Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX)’s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $15.40 and last traded at $15.20, with a volume of 30,143 shares traded. The stock had previously closed at $14.70.

Separately, Zacks Investment Research cut Dipexium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 24th.

The firm’s market cap is $158.93 million. The stock has a 50-day moving average price of $12.51 and a 200-day moving average price of $10.73.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/dipexium-pharmaceuticals-inc-dprx-reaches-new-52-week-high-at-15-40.html

Dipexium Pharmaceuticals (NASDAQ:DPRX) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.52) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.02. On average, equities analysts anticipate that Dipexium Pharmaceuticals Inc. will post ($2.10) earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in DPRX. Lombard Odier Asset Management USA Corp bought a new position in shares of Dipexium Pharmaceuticals during the second quarter worth approximately $1,507,000. Raymond James & Associates acquired a new stake in shares of Dipexium Pharmaceuticals during the second quarter worth $312,000. Timpani Capital Management LLC raised its stake in shares of Dipexium Pharmaceuticals by 45.4% in the second quarter. Timpani Capital Management LLC now owns 64,124 shares of the company’s stock worth $635,000 after buying an additional 20,014 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of Dipexium Pharmaceuticals by 19.6% in the second quarter. BlackRock Fund Advisors now owns 15,674 shares of the company’s stock worth $155,000 after buying an additional 2,568 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Dipexium Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 158,297 shares of the company’s stock worth $1,569,000 after buying an additional 12,670 shares in the last quarter. 24.78% of the stock is currently owned by institutional investors and hedge funds.

About Dipexium Pharmaceuticals

Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).

5 Day Chart for NASDAQ:DPRX

Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.